Find out about financial assistance for patients
For US residents only.
ZYKADIA® (ceritinib) is a prescription medicine used to treat non-small cell lung cancer (NSCLC) that is caused by a defect in a gene called ALK, which is short for anaplastic lymphoma kinase.
ZYKADIA is used to treat people who have been diagnosed with ALK-positive (ALK+) NSCLC that has spread to other parts of the body (metastatic) and who have taken the medicine crizotinib, but their NSCLC worsened or they could not tolerate taking crizotinib.
The effectiveness of ZYKADIA in these patients is based on a study that measured 2 types of response to treatment (response rate and duration of response). There is no clinical information available to show if patients treated with ZYKADIA live longer or if their symptoms improve. There are ongoing studies to find out how ZYKADIA works over a longer period of time. It is not known if ZYKADIA is safe and effective in children.
How ZYKADIA works
The ALK gene is thought to play a critical role in the growth of some NSCLCs. ZYKADIA is an ALK inhibitor, which means it may block the action of the ALK gene. It's believed that this helps to shrink or slow cancer growth.
Understand your disease, treatment options, and what you may expect while taking ZYKADIA® (ceritinib)
See a list of questions you may want to discuss at your next appointment (PDF)